Unani Perspectives on Dyslipidemia: An Integrative Review of Classical Concepts and Contemporary Relevance
Abstract
Background: This review examines dyslipidemia from both Unani and contemporary perspectives. Dyslipidemia is one of the most prevalent pathological conditions in modern times, primarily resulting from unhealthy dietary habits and sedentary lifestyles. Due to its high atherogenic potential, it is a major contributor to systemic disorders, particularly cardiovascular diseases and cerebrovascular accidents. In Unani medicine, dyslipidemia is attributed to the predominance of Baroodat (coldness) in the liver and the body, which disrupts the phlegmatic balance, impairs fat metabolism, and leads to abnormal accumulation. Accordingly, therapeutic interventions that temper hepatic and systemic coldness and restore metabolic harmony may offer significant benefits
Methods: Literature for this study was obtained from electronic databases, including PubMed, Web of Science, ScienceDirect, EMBASE, Google Scholar, ResearchGate, and Elsevier, as well as from major resource libraries containing Unani books and manuscripts relevant to the topic.
Results: Lipids and phlegm share significant similarities in origin, nature, pathophysiology, and complications. Despite differences in terminology, both systems converge common outcomes such as vascular obstruction, metabolic inefficiency, and heightened cardiovascular risk. This suggests that classical descriptions of Balghamī disorders may represent early interpretations of lipid dysregulation.
Conclusion: Combining biomedical and Unani perspectives provides a more integrated view of dyslipidemia. Such an approach can enhance early recognition, guide context-specific interventions, and contribute to better cardiovascular risk management.
Keywords: Dyslipidaemia, lipids, Phlegm, Phlegmatic disorders, Unani Medicine
Keywords:
Dyslipidaemia, lipids, Phlegm, Phlegmatic disorders, Unani MedicineDOI
https://doi.org/10.22270/jddt.v15i12.7469References
1. Shlomo Melmed, Robert Hardin Williams, Allison B. Goldfine, Ronald Koenig; Williams Textbook of Endocrinology. 12th ed. Elsevier; 2011.
2. INSTITUTE FOR HEALTH METRICS AND EVALUATION. Global Burden of Disease 2021. UNIVERSITY OF WASHINGTON.
3. Hippocrates, Translated by Ḥunayn ibn Isḥāq. Al-Fuṣūl al-Ibuqrāṭīya Fī al-Uṣūl al-Ṭibbīya [The Aphorisms of Hippocrates]. (John Tytler, ed.). Calcutta: Education Press; 1832.
4. Jalinoos, Translated by Hakeem Syed Zillur Rehman. Kitab Fil Mizaj. International Printing Press; 2008.
5. Hakeem Muhammad Akbar Arzani, Translated by: Hakeem Ghulam Hussain Kintoori. Kamilus Sana. Vol 1. Idarah Kitabu Shifa; 2010.
6. Ibn Sina. Al Qanoon Fit Tib. Vol 1. Idarah Kitabu Shifa
7. Ibn Sina, urdu translated by Allama Kabeerudin. Kulliyat-e-Qanoon. Aijaz publication house; 2006.
8. Urooj S, Jahangir U, Maaz M, Azam R. Dyslipidemia from Unani prospective and its management with Safoof e Muhazzil: An update. Phytomedicine Plus. 2021;1(4):100103. https://doi.org/10.1016/j.phyplu.2021.100103
9. Alamah Burhanuddin Nafees translated by Hakeem Kabiruddin. Kulliyat-i-Nafeesi. Vol 1.; 1934.
10. Kousar Chandpori. Muajazul Qanoon. CCRUM; 1998.
11. Abu Sahl Ibn Esa Ibn Yahya Ibn Ibrahim Al Maseehi. Kitabul Mu'atah Fit Tib. Vol 1. 1st ed. CCRUM; 2008.
12. Sharfu al-din Ismail Jurjani. Zakirah Khwarzam Shahi. Vol 2. Idarah Kitab ul-Shifa; 2010.
13. Abu Bakr Muhammad Ibn Zakarya Razi. Kitab Ul-Hawi. CCRUM; 2008.
14. Abul Waleed Ibn Rushd. Kitabul Kulliyat. Vol 1. CCRUM; 1987.
15. Abu ul Hassan Ali ibn Sahl Raban Tabri. Firdous Ul-Hikmat. Idarah Kitabu Shifa; 2010.
16. Avicenna(Abu Ali al-Husayn ibn Abd Allah ibn sina), Adapted by Laleh Bakhtiar, Translated by:O.Cameron Gruner and Mazar H. Shah. The Canon of Medicine. Vol 1. 22nd ed.; 1999.
17. Gupta A. Digestion and Absorption of Lipids. In: Comprehensive Biochemistry for Dentistry. Springer Singapore; 2019:441-450. https://doi.org/10.1007/978-981-13-1035-5_16
18. Sharfuddin Ismail Jurjani. Zakheera Kharzam Shahi. Vol 5. Idarah Kitabu Shifa; 2010.
19. Coelho M, Oliveira T, Fernandes R. State of the art paper Biochemistry of adipose tissue: an endocrine organ. Archives of Medical Science. 2013;2:191-200. https://doi.org/10.5114/aoms.2013.33181 PMid:23671428 PMCid:PMC3648822
20. Tahseen Z, Sofi G, Bin Heyat MB, Jahan N, Rashid A. Exploring Obstruction and Deobstruent Drugs in Unani Medicine: A Comprehensive Survey and Future Directions. Altern Ther Health Med. 2024;30(7):20-27.
21. Hakeem Muhammad Azam Khan. Akseer I-Azam. Idarah Kitabu Shifa; 2011.
22. Basaranoglu M, Neuschwander-Tetri BA. Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis. Gastroenterol Hepatol (N Y). 2006;2(4):282-291.
23. Hamburg NM, Creager MA. Pathophysiology of Intermittent Claudication in Peripheral Artery Disease. Circulation Journal. 2017;81(3):281-289. https://doi.org/10.1253/circj.CJ-16-1286 PMid:28123169
24. Taddei C, Zhou B, Bixby H, et al. Repositioning of the global epicentre of non-optimal cholesterol. Nature. 2020;582(7810):73-77. https://doi.org/10.1038/s41586-020-2338-1 PMid:32494083 PMCid:PMC7332422
25. Sawhney JPS, Ramakrishnan S, Madan K, et al. CSI clinical practice guidelines for dyslipidemia management: Executive summary. Indian Heart J. 2024;76:S6-S19. https://doi.org/10.1016/j.ihj.2023.11.271 PMid:38052658 PMCid:PMC11019331
26. Wei S, Nguyen TT, Zhang Y, Ryu D, Gariani K. Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management. Front Endocrinol (Lausanne). 2023;14. https://doi.org/10.3389/fendo.2023.1185221 PMid:37455897 PMCid:PMC10344359
27. Gao M jiao, Xue H zhong, Cai R, et al. A Preliminary Study on Infrared Thermograph of Metabolic Syndrome. Front Endocrinol (Lausanne). 2022;13. https://doi.org/10.3389/fendo.2022.851369 PMid:35498430 PMCid:PMC9042650
28. Cai C, Mai Z, Deng T, et al. Impact of dyslipidemia on 24-h urine composition in adults without urolithiasis. Lipids Health Dis. 2018;17(1):250. https://doi.org/10.1186/s12944-018-0899-x PMid:30400932 PMCid:PMC6220564
29. Wang D, Chen J, Zhou Y, et al. Association between sleep duration, sleep quality and hyperlipidemia in middle-aged and older Chinese: The Dongfeng-Tongji Cohort Study. Eur J Prev Cardiol. 2019;26(12):1288-1297. https://doi.org/10.1177/2047487319843068 PMid:30966819
30. Smith AG, Singleton JR. Obesity and hyperlipidemia are risk factors for early diabetic neuropathy. J Diabetes Complications. 2013;27(5):436-442. https://doi.org/10.1016/j.jdiacomp.2013.04.003 PMid:23731827 PMCid:PMC3766404
31. Zhao Y, Zhang H, Cheng J, Zou Y, Zhang D, Duan X. Association between Dyslipidaemia and Cognitive Impairment: A Meta-Analysis of Cohort and Case-Control Studies. J Integr Neurosci. 2024;23(2). https://doi.org/10.31083/j.jin2302040 PMid:38419448
32. Wang Q, Zang F, He C, Zhang Z, Xie C. Dyslipidemia induced large-scale network connectivity abnormality facilitates cognitive decline in the Alzheimer's disease. J Transl Med. 2022;20(1):567. https://doi.org/10.1186/s12967-022-03786-w PMid:36474263 PMCid:PMC9724298
33. Dolatshahi P, Moeini R, Mokabberinejad R, Ahmad Dar F, Alizadeh M, Mojahedi M. A Review of Cold-Wet Mizaj and Phlegm Dominance Indices in Persian Medicine. Shiraz E Med J. 2024;25(8). https://doi.org/10.5812/semj-138252
34. Jean-Louis G, Zizi F, Clark LT, Brown CD, McFarlane SI. Obstructive Sleep Apnea and Cardiovascular Disease: Role of the Metabolic Syndrome and Its Components. Journal of Clinical Sleep Medicine. 2008;04(03):261-272. https://doi.org/10.5664/jcsm.27191 PMid:18595441 PMCid:PMC2546461
35. Markelić I, Hlapčić I, Rogić D, et al. Lipid profile and atherogenic indices in patients with stable chronic obstructive pulmonary disease. Nutrition, Metabolism and Cardiovascular Diseases. 2021;31(1):153-161. https://doi.org/10.1016/j.numecd.2020.07.039 PMid:32981798
36. G.E. Vrentzos, K.I. Paraskevas, D.P. Mikhailidis. Dyslipidemia as a Risk Factor for Erectile Dysfunction. Curr Med Chem. 2007;14(16):1765-1770. https://doi.org/10.2174/092986707781058931 PMid:17627514
37. Li A, Zheng N, Ding X. Mitochondrial abnormalities: a hub in metabolic syndrome-related cardiac dysfunction caused by oxidative stress. Heart Fail Rev. 2022;27(4):1387-1394. https://doi.org/10.1007/s10741-021-10109-6 PMid:33950478 PMCid:PMC9197868
38. Muhzab al-Din Ibn Hanbal Baghdadi. Kitab Mukhtaraat Fit Tib. Vol 1. CCRUM; 2004.
39. Hakeem Ali bin Husain Arzani, Hussain M. H. translator. Tibbe Akbar. Faisal Publications
40. Murad S, Saif S, Ghaffar A, Khalid N, Sheikh RA, Sheikh DM. HERBS: Novel Considerations in Unani Medicine. Austin Journal of Allergy. 2019;6(1):10346.
41. Abdur Rasheed, M. A. Siddiqui, Javed A. Khan. Therapeutic evaluation of Kalonji (Nigella sativa) in dyslipidemia - A randomized control trial. Medical Journal of Islamic World Academy of Sciences. 2014;22(3):111-116. https://doi.org/10.12816/0008181
42. Quamri MA, Wahab A, Alam MA, Ali BF. Efficacy of Majoon-e-Seer Alvi Khan in dyslipidemia: a single blind randomized standard controlled clinical trial. Drug Metab Pers Ther. 2021;36(4):271-279. https://doi.org/10.1515/dmpt-2021-0117 PMid:34821127
43. Alam K, Sheikh H, Samad MdA. Clinical Effect of Poly Herbal Unani Formulation on Dyslipidemia- A Randomized Trial. Turkish Journal of Agriculture - Food Science and Technology. 2023;11(10):1892-1904. https://doi.org/10.24925/turjaf.v11i10.1892-1904.6185
44. Nirmala Devi MK, Adil MA, Nikhat Shaikh, et al. The Effects of Unani Formulation Jawarish Bisbasa in Dyslipidaemia and Anthropometric Parameters Associated with Central Obesity- An open-label clinical Trial. Indian J Public Health Res Dev. 2024;15(4):346-353. https://doi.org/10.37506/wdzz3567
45. Sazid Alam, MD Anzar Alam, Ghulamuddin Sofi, Mohd. Qudratullah Khan, Shabnam Ansari. A Randomized single blind controlled clinical trial on safety and efficacy of a Unani formulation (Itrifal-e-Sagheer) in dyslipidemia. CELLMED. 2020;10(1):8-10.
Published
Abstract Display: 139 
PDF Downloads: 70 PDF Downloads: 22 How to Cite
Issue
Section
Copyright (c) 2025 Ishrat Rasool , Sadique Ali , Niyazi Abdullah Khizar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.